# Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/fulvestrant-plus-vistusertib-vs-fulvestrant-plus-everolimus-vs-fulvestrant-alone/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Peter Schmid,Matthias Zaiß,Catherine Harper‐Wynne,M. Ferreira,Sidharth Dubey,Stephen Chan,Andreas Makris,Gia Nemsadze,Adrian Murray Brunt,Sherko Küemmel,Isabel Ruíz-Camps,Antonia Perelló,Anne Kendall,Janet E. Brown,Hartmut Kristeleit,John Conibear,Cristina Saura,Julien Grenier,Mahr Karoly,Michael Schenker,Joohyuk Sohn,Keun Seok Lee,Christopher J. Shepherd,Elisabeth Oelmann,Shah‐Jalal Sarker,Aaron Prendergast,Patricia Marosics,Atiyyah Moosa,Cheryl Lawrence,Carike Coetzee,Kelly Mousa,Javier Cortés |
| Citations | 90 |
| DOI | 10.1001/jamaoncol.2019.2526 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | https://jamanetwork.com/journals/jamaoncology/articlepdf/2749178/jamaoncology_schmid_2019_oi_190056_1607525610.29516.pdf |
| OpenAlex ID | https://openalex.org/W2970223488 |
| PMID | 31465093 |
| Type | article |
| Year | 2019 |

## Paper authors

- [Shah‐Jalal Sarker](https://scholariq.org/researchers/shah-jalal-sarker/)

## Paper journal

- [JAMA Oncology](https://scholariq.org/journals/jama-oncology/)

## Paper primary topic

- [PI3K/AKT/mTOR signaling in cancer](https://scholariq.org/topics/pi3k-akt-mtor-signaling-in-cancer/)

## Paper topics

- [PI3K/AKT/mTOR signaling in cancer](https://scholariq.org/topics/pi3k-akt-mtor-signaling-in-cancer/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Estrogen and related hormone effects](https://scholariq.org/topics/estrogen-and-related-hormone-effects/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.